ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics … – GlobeNewswire (press release)

New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics …GlobeNewswire (press release)ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of … Continue reading

2018-05-08 Michael Zand NEWS

GE launches temperature controlled processing tech for CAR T-cell therapy – BioPharma-Reporter.com

BioPharma-Reporter.comGE launches temperature controlled processing tech for CAR T-cell therapyBioPharma-Reporter.comThe technology can be applied to any type of cellular therapy, including chimeric antigen receptor (CAR) T-cell therapy. “A new softwar… Continue reading

2018-05-08 Michael Zand NEWS

Stem cells to cure life threatening illnesses [Sci Tech] – africanews

Continue reading

2018-05-08 Michael Zand NEWS

CRISPR-guided proximity labeling—dissecting gene transcription’s … – Phys.Org


africanews

Stem cells to cure life threatening illnesses [Sci Tech]
africanews
When harvested and re-injected into humans, the stem cells help re-grow and regenerate cells that were damaged or lost due to illness and injury. Also, we tell you why news about three black girls in the United States named among finalists for NASA’s …
AGU concludes Stem Cell ConferenceBahrain News Agency
Fasting may boost stem cell regeneration, says studyInformation-Analytic Agency NEWS.am

all 27 news articles »

Continue reading

2018-05-08 Michael Zand NEWS

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62 – Reuters

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62ReutersMay 8 (Reuters) – CRISPR Therapeutics AG: * CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS. * CRISPR THERAPEUTICS AG – ON TRACK TO BEGIN … Continue reading

2018-05-08 Michael Zand NEWS

Two Day Stem Cells in Drug Discovery & Toxicity Screening Conference: San Diego, CA, United States – October 4th … – PR Newswire (press release)

Two Day Stem Cells in Drug Discovery & Toxicity Screening Conference: San Diego, CA, United States – October 4th …PR Newswire (press release)Stem Cells in Drug Discovery, and Toxicity Screening 2018 brings together researchers from around the wor… Continue reading

2018-05-08 Michael Zand NEWS

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial – Mass Device


Phys.Org

CRISPR-guided proximity labeling—dissecting gene transcription’s …
Phys.Org
More powerful than previous methods, a new approach for tagging and harvesting DNA-associated proteins from cells could open deeper insights into …
New CRISPR technology ‘knocks out’ yeast genes with single-point …Science Daily
Researchers modify CRISPR to knock out single genes in yeastNews-Medical.net

all 3 news articles »

Continue reading

2018-05-08 Michael Zand NEWS

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results – GlobeNewswire (press release)


Mass Device

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
Mass Device
OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer …

Continue reading

2018-05-08 Michael Zand NEWS
  • 1
  • …
  • 131
  • 132
  • 133
  • 134
  • 135
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Post Analyst

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
GlobeNewswire (press release)
ZUG, Switzerland and CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today provided a business update and …
Investors Jumping Ship on Skechers USA, Inc. (SKX), CRISPR Therapeutics AG (CRSP)Post Analyst
The Market’s 4 Best Stocks to Buy Right NowYahoo Finance

all 74 news articles »